TENYES-D (Dapagliflozin + Teneligliptin)

MOA

1. Dapagliflozin inhibits SGLT2 in kidneys
2. Increases glucose excretion via urine
3. Reduces blood glucose independently of insulin
4. Teneligliptin inhibits DPP-4 enzyme
5. Increases incretin hormone levels
6. Enhances insulin secretion
7. Reduces glucagon levels

Uses

1. Type 2 diabetes mellitus
2. Poor glycemic control
3. Combination therapy
4. Obese diabetic patients
5. Cardiovascular risk reduction
6. Diabetic kidney protection
7. Long-term glucose management

Side Effects

1. Urinary tract infections
2. Genital infections
3. Increased urination
4. Dehydration
5. Hypoglycemia (rare)
6. Dizziness
7. Nausea

Precautions

1. Maintain hydration
2. Monitor renal function
3. Avoid in severe kidney disease
4. Watch for infections
5. Not for type 1 diabetes
6. Monitor blood sugar regularly
7. Use under medical supervision

Tags: Dapagliflozin + Teneligliptin